Your session is about to expire
← Back to Search
Group 2 for Postoperative Nausea
Phase 1 & 2
Waitlist Available
Led By Amani H Abdel-wahab, MD
Research Sponsored by Amani Hassan Abdel-Wahab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 24 hours postoperative
Awards & highlights
Summary
Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.
Eligible Conditions
- Postoperative Nausea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ first 24 hours postoperative
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 24 hours postoperative
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
nausea and/or vomiting score
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: Group 2Active Control1 Intervention
patients will receive oral 5 mg Olanzapine tablets one hour preoperatively
Group II: Group 3Active Control1 Intervention
patients will receive oral 10 mg Olanzapine tablets one hour preoperatively
Group III: Group 1Placebo Group1 Intervention
patients will receive oral placebo tablets one hour preoperatively
Find a Location
Who is running the clinical trial?
Amani Hassan Abdel-WahabLead Sponsor
1 Previous Clinical Trials
60 Total Patients Enrolled
Amani H Abdel-wahab, MDPrincipal InvestigatorAssiut University
3 Previous Clinical Trials
345 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger